Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market size was valued at US$ 2389 million in 2024 and is forecast to a readjusted size of USD 2142 million by 2031 with a CAGR of -1.6% during review period.

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.

Affecting 70-80% of patients undergoing chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is one of chemotherapy"s most debilitating side effects, often attributed as a leading cause of premature discontinuation of cancer treatment.

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs key players include Haisco, Merck, Mundipharma, Qilu Pharma, Heron Therapeutics, Teva, etc. Global top six manufacturers hold a share about 30%.

North America is the largest market, with a share about 35%, followed by Europe and Asia-Pacific, both have a share about 60 percent.

In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 70%. And in terms of application, the largest application is Acute CINV, followed by Delayed CINV and Breakthrough CINV.

This report is a detailed and comprehensive analysis for global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2020-2031

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2020-2031

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Units), and average selling prices (US$/Unit), 2020-2031

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (M Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche, Mylan, Baxter, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Others

Market segment by Application
Acute CINV
Delayed CINV
Breakthrough CINV
Others

Major players covered
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs, with price, sales quantity, revenue, and global market share of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs from 2020 to 2025.

Chapter 3, the Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs.

Chapter 14 and 15, to describe Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs sales channel, distributors, customers, research findings and conclusion.